Curative liver resection: Standard radical hepatectomy performed according to 2024 HCC guidelines. No neoadjuvant or adjuvant therapies administered. Follows institutional surgical protocols for BCLC 0-A HCC.
Real-world multimodal therapy: Curative resection combined with clinically indicated therapies (e.g., TACE, targeted drugs, immunotherapy) as per treating physician's decision. Treatments recorded but not protocol-mandated.
Study summary
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.
The main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged 18-75 years, regardless of gender.
* BCLC stage 0-A, scheduled for curative liver resection.
* Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).
* Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.
* Child-Pugh liver function score ≤7.
* ECOG Performance Status (PS) 0-1.
* No severe organic diseases of the heart, lungs, brain, or other vital organs.
Exclusion Criteria:
* Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).
* Postoperative pathology confirms non-HCC diagnosis.
* Pregnant or lactating women.
* History of organ transplantation.
* Inability to comply with the study protocol or follow-up schedule.
Primary outcome measure(s)
Accuracy of AI Model in Predicting Aggressive HCC Recurrence (AUC) — 2 years post-surgery The area under the receiver operating characteristic curve (AUC) of the multimodal deep learning model (PRE/POST) for predicting postoperative recurrence beyond Milan criteria within 2 years after resection, validated against actual imaging/histopathology-confirmed recurrence patterns.
Unit : Dimensionless (0-1)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.